27
Aug
2026
RevMed’s Watershed, Roivant Goes Commercial, & Roche’s Blood Test for Alzheimer’s
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Aug
2026
A Vaccine for Epstein-Barr Virus: Gary Nabel on The Long Run
Gary Nabel is today’s guest on The Long Run. Gary is the CEO of Weston, Mass.-based ModeX Therapeutics. The company has a platform for making multi-specific biologics into vaccines and cancer treatments. ModeX was founded in 2020, building on work that started at Sanofi when Nabel was the chief scientific officer there. The initial application of this technology, currently in... Read More
20
Aug
2026
Moderna’s Home Run, Amylyx Bounces Back, & Enveda Advances Workout-in-a-Pill
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Aug
2026
9 Young Scientists to Watch: the Timmerman Traverse Fellows at Damon Runyon
Our community’s steadfast support of science is more important than ever given the tenuous state of federal research funding. Teams of biotech executives and investors have raised $3.9 million for high-risk/high-reward cancer research since 2024 as part of the Timmerman Traverse for Damon Runyon Cancer Research Foundation. The Traverse has created fun outdoor experiences and lasting friendships. We’ve hit the... Read More
17
Aug
2026
Harell Data Debuts With $15M To Change Incentives, Speed Up AI Drug Discovery
The Protein Data Bank was the unsung hero that made AlphaFold possible. For decades, the structural biologists, biochemists and others who put carefully curated protein structures in the public domain laid down the conditions for AI to eventually do something useful – predicting protein structures in this case. Those scientists never got a nickel. This is just one of many... Read More
13
Aug
2026
Jazz Scoops Up Epilepsy Drug, Boulevard Aims for Immune Reset, & AbCellera Matures
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Aug
2026
Genetic Medicines For Kidney Diseases: Jason Coloma on The Long Run
Jason Coloma is today’s guest on The Long Run. Jason is the CEO of South San Francisco-based Maze Therapeutics. The company is developing small molecule drugs to halt or potentially reverse kidney diseases. The drug discovery work at Maze is grounded in human genetics, looking at large pools of data to see how variants of one kind or another can... Read More
6
Aug
2026
Takeda Wins First-in-Class Orexin OK, Lilly’s Obesity Money Gusher, & Three New IPOs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Aug
2026
LifeMine, In Verdine’s Big Year, Raises $263M For Safer Drug for Organ Transplants
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Jul
2026
J&J Buys In Vivo CAR-T, Sarepta’s New Boss, & Three IPOs in the Queue
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Jul
2026
Inhalable Medicines for Severe Lung Diseases: Lyn Baranowski on The Long Run
Lyn Baranowski is today’s guest on The Long Run. Lyn is the CEO of Boston-based Avalyn Pharma. The company is developing inhalable drugs for rare, severe lung diseases, such as pulmonary fibrosis and other interstitial lung diseases. Avalyn has taken a couple of small molecules that are given orally, and remade them into inhalable drugs so they can be more... Read More
23
Jul
2026
Dimension Hauls In $800M, Arrowhead Nails Triglycerides, Tempus Buys Personalis
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Jul
2026
Merck Oral PSCK9 OK’d, Vertex Snaps Up Crinetics, Lilly Buys a Psychedelic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Jul
2026
A Schizophrenia Drug Patients Can Stick With: Heather Turner on The Long Run
Heather Turner is today’s guest on The Long Run. Heather is the CEO of New York-based LB Pharmaceuticals. It’s developing treatments for serious mental health disorders such as schizophrenia, depression, and bipolar disorder. The company is running late-stage clinical trials for its lead drug candidate, LB102. It’s a methylated derivative of amisulpride, a benzamide antipsychotic. It’s approved in more than... Read More
30
Jun
2026
Precision Cancer Drugs and Combos: Troy Wilson on The Long Run
Troy Wilson is today’s guest on The Long Run. Troy is the co-founder and CEO of San Diego-based Kura Oncology. The company, founded in 2014, has gone all the way through R&D to develop its own novel cancer drug. It’s called ziftomenib (brand name Komzifti). It’s an oral pill that inhibits a target called menin. Ziftomenib was approved by the... Read More
25
Jun
2026
AbbVie Acquires Apogee, FDA Changes Tune on RegenxBio, & Merck Seizes TL1A Lead
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Jun
2026
Ollin Advances with $330M to Challenge Roche in DME & Wet AMD
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Jun
2026
Kardigan Continues IPO Trend & FDA Reconsiders UniQure and Moderna
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Jun
2026
Small Molecules To Correct Disease: Sri Kosuri on The Long Run
Sri Kosuri is today’s guest on The Long Run. Sri is the co-founder and CEO of Emeryville, California-based Octant Bio. The company is developing oral small molecule drugs that are designed to correct protein misfolding and mistrafficking. Quite a few rare diseases, cancers, and metabolic disorders are thought to be amenable to this strategy. Octant’s work starts with a platform... Read More
11
Jun
2026
Parabilis IPO Pops, J&J Buys More Degraders, & GSK’s Precision Oncology Bet
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.